Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) traded up 3.4% during trading on Tuesday after JMP Securities raised their price target on the stock from $9.00 to $20.00. JMP Securities currently has an outperform rating on the stock. Corbus Pharmaceuticals Holdings traded as high as $10.30 and last traded at $8.55, with a volume of 1,543,122 shares trading hands. The stock had previously closed at $8.85.

Other analysts have also recently issued reports about the company. Aegis reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Monday. Noble Financial reissued a “buy” rating and set a $19.00 target price on shares of Corbus Pharmaceuticals Holdings in a research note on Friday, November 11th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $17.00 target price on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, October 26th.

In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran bought 30,800 shares of the stock in a transaction that occurred on Thursday, September 8th. The stock was acquired at an average cost of $5.12 per share, with a total value of $157,696.00. Following the purchase, the chief financial officer now owns 330,110 shares in the company, valued at $1,690,163.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sean F. Moran bought 17,900 shares of the stock in a transaction that occurred on Friday, August 26th. The shares were acquired at an average cost of $3.92 per share, with a total value of $70,168.00. Following the completion of the purchase, the chief financial officer now owns 299,310 shares in the company, valued at approximately $1,173,295.20. The disclosure for this purchase can be found here. Corporate insiders own 11.60% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at $508,000. Bank of New York Mellon Corp acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at $155,000. Milestone Group Inc. acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at $102,000. BlackRock Institutional Trust Company N.A. boosted its position in shares of Corbus Pharmaceuticals Holdings by 14.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 216,139 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 27,000 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 13,222 shares in the last quarter. 25.39% of the stock is owned by institutional investors.

The firm has a 50-day moving average of $7.18 and a 200 day moving average of $4.45. The firm’s market capitalization is $356.55 million.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.